4Q Revenues: $210.0 million (flat)
4Q Loss: $23.1 million (loss of $9.9 million in 4Q11)
YTD Revenues: $749.1 million (+7%)
YTD Loss: $106.7 million (loss of $16.4 million YTD11)
Comments: Commercial manufacturing revenues in the quarter were $172.7 million, up 18%, and for the year were $610.7 million, up 7%. Pharmaceutical Development Services revenues in the quarter were $37.5 million, up 7%, and for the year were $138.4 million, up 9%. The loss before discontinued operations was $106.4 million YTD compared to a loss of $15.8 million last year, primarily due to the asset impairment charge of $57.9 million related to closing the Swindon, UK facility.